Allergan (AGN) Strong With or Without DARPin - RBC
Analysts at RBC Capital think the market overreacted to news about Allergen's (NYSE: AGN) DARPin. Today Allergan's CEO said data on DARPin does not support Phase 3 trials, which will delay approval by 1-2 years. This sent shares lower by well over 10 percent, but RBC Capital thinks Allergan is strong with or with or without DARPin. Analysts think shares should be bought on weakness.
RBC Capital has an Outperform rating on Allergen with a price target of $123.00
For an analyst ratings summary and ratings history on Allergen (NYSE: AGN) click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $113.55 yesterday, with a 52 week range of $81.28-$116.45.
RBC Capital has an Outperform rating on Allergen with a price target of $123.00
For an analyst ratings summary and ratings history on Allergen (NYSE: AGN) click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $113.55 yesterday, with a 52 week range of $81.28-$116.45.